{"id":"https://openalex.org/W1985269587","doi":"https://doi.org/10.1182/blood.v98.6.1708","title":"Phase 1 study of polyethylene glycol formulation of interferon \u03b1-2B (Schering 54031) in Philadelphia chromosome\u2013positive chronic myelogenous leukemia","display_name":"Phase 1 study of polyethylene glycol formulation of interferon \u03b1-2B (Schering 54031) in Philadelphia chromosome\u2013positive chronic myelogenous leukemia","publication_year":2001,"publication_date":"2001-09-15","ids":{"openalex":"https://openalex.org/W1985269587","doi":"https://doi.org/10.1182/blood.v98.6.1708","mag":"1985269587","pmid":"https://pubmed.ncbi.nlm.nih.gov/11535501"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v98.6.1708","doi":"https://doi.org/10.1182/blood.v98.6.1708","is_oa":true,"landing_page_url":"https://doi.org/10.1182/blood.v98.6.1708","pdf_url":"https://ashpublications.org/blood/article-pdf/98/6/1708/1676904/h8180101708.pdf","source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://ashpublications.org/blood/article-pdf/98/6/1708/1676904/h8180101708.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5011529063","display_name":"Moshe Talpaz","orcid":"https://orcid.org/0000-0003-3361-3981","observed_orcids":["https://orcid.org/0000-0003-3361-3981"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]},{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Moshe Talpaz","raw_affiliation_strings":["From the Departments of Bioimmunotherapy and Leukemia, M. D. Anderson Cancer Center, Houston, TX, and Schering-Plough Research Institute, Kenilworth, NJ","Merck"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Bioimmunotherapy and Leukemia, M. D. Anderson Cancer Center, Houston, TX, and Schering-Plough Research Institute, Kenilworth, NJ","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"Merck","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102743501","display_name":"Susan Mary O'Brien","orcid":"https://orcid.org/0000-0003-3386-6540","observed_orcids":["https://orcid.org/0000-0003-3386-6540"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]},{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Susan O'Brien","raw_affiliation_strings":["From the Departments of Bioimmunotherapy and Leukemia, M. D. Anderson Cancer Center, Houston, TX, and Schering-Plough Research Institute, Kenilworth, NJ","Merck"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Bioimmunotherapy and Leukemia, M. D. Anderson Cancer Center, Houston, TX, and Schering-Plough Research Institute, Kenilworth, NJ","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"Merck","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004071908","display_name":"Esther H. Rose","orcid":"https://orcid.org/0000-0002-7572-1596","observed_orcids":["https://orcid.org/0000-0002-7572-1596"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]},{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Esther Rose","raw_affiliation_strings":["From the Departments of Bioimmunotherapy and Leukemia, M. D. Anderson Cancer Center, Houston, TX, and Schering-Plough Research Institute, Kenilworth, NJ","Merck"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Bioimmunotherapy and Leukemia, M. D. Anderson Cancer Center, Houston, TX, and Schering-Plough Research Institute, Kenilworth, NJ","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"Merck","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Samir Gupta","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]},{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Samir Gupta","raw_affiliation_strings":["From the Departments of Bioimmunotherapy and Leukemia, M. D. Anderson Cancer Center, Houston, TX, and Schering-Plough Research Institute, Kenilworth, NJ","Merck"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Bioimmunotherapy and Leukemia, M. D. Anderson Cancer Center, Houston, TX, and Schering-Plough Research Institute, Kenilworth, NJ","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"Merck","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103417990","display_name":"Jianqin Shan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]},{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jianqin Shan","raw_affiliation_strings":["From the Departments of Bioimmunotherapy and Leukemia, M. D. Anderson Cancer Center, Houston, TX, and Schering-Plough Research Institute, Kenilworth, NJ","Merck"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Bioimmunotherapy and Leukemia, M. D. Anderson Cancer Center, Houston, TX, and Schering-Plough Research Institute, Kenilworth, NJ","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"Merck","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015101485","display_name":"J\u00f6rge E. Cortes","orcid":"https://orcid.org/0000-0002-8636-1071","observed_orcids":["https://orcid.org/0000-0002-8636-1071"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jorge Cortes","raw_affiliation_strings":["From the Departments of Bioimmunotherapy and Leukemia, M. D. Anderson Cancer Center, Houston, TX, and Schering-Plough Research Institute, Kenilworth, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Bioimmunotherapy and Leukemia, M. D. Anderson Cancer Center, Houston, TX, and Schering-Plough Research Institute, Kenilworth, NJ","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061285204","display_name":"Francis Joseph Giles","orcid":"https://orcid.org/0000-0002-6919-0231","observed_orcids":["https://orcid.org/0000-0002-6919-0231"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Francis J. Giles","raw_affiliation_strings":["From the Departments of Bioimmunotherapy and Leukemia, M. D. Anderson Cancer Center, Houston, TX, and Schering-Plough Research Institute, Kenilworth, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Bioimmunotherapy and Leukemia, M. D. Anderson Cancer Center, Houston, TX, and Schering-Plough Research Institute, Kenilworth, NJ","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046097970","display_name":"Stefan H Faderl","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]},{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stefan Faderl","raw_affiliation_strings":["From the Departments of Bioimmunotherapy and Leukemia, M. D. Anderson Cancer Center, Houston, TX, and Schering-Plough Research Institute, Kenilworth, NJ","Merck"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Bioimmunotherapy and Leukemia, M. D. Anderson Cancer Center, Houston, TX, and Schering-Plough Research Institute, Kenilworth, NJ","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"Merck","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5090435894","display_name":"Hagop M. Kantarjian","orcid":"https://orcid.org/0000-0002-1908-3307","observed_orcids":["https://orcid.org/0000-0002-1908-3307"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hagop M. Kantarjian","raw_affiliation_strings":["From the Departments of Bioimmunotherapy and Leukemia, M. D. Anderson Cancer Center, Houston, TX, and Schering-Plough Research Institute, Kenilworth, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Bioimmunotherapy and Leukemia, M. D. Anderson Cancer Center, Houston, TX, and Schering-Plough Research Institute, Kenilworth, NJ","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":5.2898,"has_fulltext":true,"cited_by_count":67,"citation_normalized_percentile":{"value":0.9637946,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":97},"biblio":{"volume":"98","issue":"6","first_page":"1708","last_page":"1713"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9945999979972839,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9945999979972839,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0017999999690800905,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/philadelphia-chromosome-positive-chronic-myelogenous-leukemia","display_name":"Philadelphia chromosome-positive chronic myelogenous leukemia","score":0.8989999890327454},{"id":"https://openalex.org/keywords/interferon-alpha-therapy","display_name":"interferon-alpha therapy","score":0.6399999856948853},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8809999823570251},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.9639999866485596},{"id":"https://openalex.org/keywords/hematological-response","display_name":"hematologic response","score":0.6660000085830688},{"id":"https://openalex.org/keywords/cytogenetic-response","display_name":"cytogenetic response","score":0.9959999918937683},{"id":"https://openalex.org/keywords/treatment-resistance","display_name":"treatment resistance","score":0.3970000147819519},{"id":"https://openalex.org/keywords/neurotoxicity","display_name":"neurotoxicity","score":0.7369999885559082},{"id":"https://openalex.org/keywords/myelosuppression","display_name":"myelosuppression","score":0.9089999794960022},{"id":"https://openalex.org/keywords/fatigue","display_name":"fatigue","score":0.4359999895095825},{"id":"https://openalex.org/keywords/liver-dysfunction","display_name":"liver dysfunction","score":0.49000000953674316}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7463895082473755},{"id":"https://openalex.org/C2776960273","wikidata":"https://www.wikidata.org/wiki/Q729735","display_name":"Chronic myelogenous leukemia","level":3,"score":0.7038694024085999},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6168646216392517},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.602938175201416},{"id":"https://openalex.org/C54400483","wikidata":"https://www.wikidata.org/wiki/Q1793202","display_name":"PEG ratio","level":2,"score":0.5668565034866333},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.4842188358306885},{"id":"https://openalex.org/C2778904597","wikidata":"https://www.wikidata.org/wiki/Q1129111","display_name":"Philadelphia chromosome","level":4,"score":0.4685315489768982},{"id":"https://openalex.org/C2909179924","wikidata":"https://www.wikidata.org/wiki/Q6046488","display_name":"Alpha interferon","level":3,"score":0.46023228764533997},{"id":"https://openalex.org/C2776964284","wikidata":"https://www.wikidata.org/wiki/Q410083","display_name":"Polyethylene glycol","level":2,"score":0.43481141328811646},{"id":"https://openalex.org/C2776461080","wikidata":"https://www.wikidata.org/wiki/Q7160835","display_name":"Pegylated interferon","level":5,"score":0.41034063696861267},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.40014466643333435},{"id":"https://openalex.org/C2776178377","wikidata":"https://www.wikidata.org/wiki/Q188269","display_name":"Interferon","level":2,"score":0.34662899374961853},{"id":"https://openalex.org/C138626823","wikidata":"https://www.wikidata.org/wiki/Q916504","display_name":"Chromosomal translocation","level":3,"score":0.14322134852409363},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.10924959182739258},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.08798959851264954},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C2780040827","wikidata":"https://www.wikidata.org/wiki/Q421862","display_name":"Ribavirin","level":4,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C2776408679","wikidata":"https://www.wikidata.org/wiki/Q708693","display_name":"Hepatitis C virus","level":3,"score":0.0},{"id":"https://openalex.org/C10138342","wikidata":"https://www.wikidata.org/wiki/Q43015","display_name":"Finance","level":1,"score":0.0},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000077190","descriptor_name":"Interferon alpha-2","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002626","descriptor_name":"Chemistry, Pharmaceutical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005500","descriptor_name":"Follow-Up Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010677","descriptor_name":"Philadelphia Chromosome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D011092","descriptor_name":"Polyethylene Glycols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011092","descriptor_name":"Polyethylene Glycols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011092","descriptor_name":"Polyethylene Glycols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011994","descriptor_name":"Recombinant Proteins","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015464","descriptor_name":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015464","descriptor_name":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D015464","descriptor_name":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D020714","descriptor_name":"Maximum Tolerated Dose","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020732","descriptor_name":"Cytogenetic Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1182/blood.v98.6.1708","doi":"https://doi.org/10.1182/blood.v98.6.1708","is_oa":true,"landing_page_url":"https://doi.org/10.1182/blood.v98.6.1708","pdf_url":"https://ashpublications.org/blood/article-pdf/98/6/1708/1676904/h8180101708.pdf","source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},{"id":"pmid:11535501","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11535501","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"Clinical Trial"}],"best_oa_location":{"id":"doi:10.1182/blood.v98.6.1708","doi":"https://doi.org/10.1182/blood.v98.6.1708","is_oa":true,"landing_page_url":"https://doi.org/10.1182/blood.v98.6.1708","pdf_url":"https://ashpublications.org/blood/article-pdf/98/6/1708/1676904/h8180101708.pdf","source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W1985269587.pdf","grobid_xml":"https://content.openalex.org/works/W1985269587.grobid-xml"},"referenced_works_count":37,"referenced_works":["https://openalex.org/W38386901","https://openalex.org/W188630774","https://openalex.org/W795773209","https://openalex.org/W1498708301","https://openalex.org/W1561844029","https://openalex.org/W1828940258","https://openalex.org/W1901923962","https://openalex.org/W1940732706","https://openalex.org/W1971801625","https://openalex.org/W1990761369","https://openalex.org/W1995050303","https://openalex.org/W2005278584","https://openalex.org/W2008131441","https://openalex.org/W2008548577","https://openalex.org/W2010012100","https://openalex.org/W2011707824","https://openalex.org/W2025574559","https://openalex.org/W2037064988","https://openalex.org/W2038990138","https://openalex.org/W2039978091","https://openalex.org/W2058190985","https://openalex.org/W2065225927","https://openalex.org/W2066736414","https://openalex.org/W2067635683","https://openalex.org/W2089697181","https://openalex.org/W2091850352","https://openalex.org/W2093312029","https://openalex.org/W2122797075","https://openalex.org/W2133647529","https://openalex.org/W2269407420","https://openalex.org/W2269564684","https://openalex.org/W2330913380","https://openalex.org/W2332630894","https://openalex.org/W2337277825","https://openalex.org/W2502670554","https://openalex.org/W2508058084","https://openalex.org/W4285719527"],"related_works":["https://openalex.org/W2017296183","https://openalex.org/W2131656137","https://openalex.org/W2562089111","https://openalex.org/W2137611006","https://openalex.org/W2020348444","https://openalex.org/W7010454696","https://openalex.org/W2078051582","https://openalex.org/W2269564684","https://openalex.org/W2002959626","https://openalex.org/W2058427042"],"abstract_inverted_index":{"Interferon":[0],"alpha":[1],"(IFN-alpha)":[2],"therapy":[3],"improves":[4],"prognosis":[5],"in":[6,56,61,135,184],"Philadelphia":[7],"chromosome":[8],"(Ph)-positive":[9],"chronic":[10,57,136],"myelogenous":[11],"leukemia":[12],"(CML).":[13],"Polyethylene":[14],"glycol":[15],"(PEG)":[16],"attached":[17],"to":[18,36,81,101,116,191,203,221],"IFN-alpha":[19,63,82,204],"prolongs":[20],"its":[21],"half-life":[22],"and":[23,46,99,107,127,146,227],"may":[24],"offer":[25],"better":[26,225],"therapy.":[27],"The":[28,110,148,213],"aims":[29],"of":[30,131,153],"this":[31],"phase":[32,150],"1":[33],"study":[34],"were":[35,67],"define":[37],"the":[38,144],"maximal":[39],"tolerated":[40,205],"dose":[41,152],"(MTD),":[42],"dose-limiting":[43],"toxicities":[44],"(DLTs),":[45],"response":[47,171,178,190],"with":[48,53,163],"PEG":[49,85,132,154,206,217],"IFN-alpha-2b.":[50],"Twenty-seven":[51],"adults":[52],"Ph(+)":[54],"CML":[55],"or":[58,74,79,195],"accelerated":[59],"phases,":[60],"whom":[62],"treatment":[64],"had":[65,70,175],"failed,":[66],"studied.":[68],"Patients":[69],"hematologic":[71,170],"(9":[72],"patients)":[73,78,194],"cytogenetic":[75,177,189,211],"resistance":[76],"(12":[77],"intolerance":[80],"(6":[83],"patients).":[84,198],"IFN-alpha-2b":[86,133,155,218],"was":[87,112,156],"given":[88],"as":[89],"a":[90,176],"weekly":[91,98],"subcutaneous":[92],"injection":[93],"starting":[94],"at":[95,114],"0.75":[96],"microg/kg":[97,158],"escalating":[100],"1.5,":[102],"3,":[103],"4.5,":[104],"6,":[105],"7.5,":[106],"9.0":[108],"microg/kg.":[109],"MTD":[111,145],"defined":[113,143],"7.5":[115],"9":[117],"microg/kg;":[118],"DLT":[119],"included":[120],"severe":[121],"fatigue,":[122],"neurotoxicity,":[123],"liver":[124],"function":[125],"abnormalities,":[126],"myelosuppression.":[128],"Longer":[129],"administration":[130],"resulted":[134],"side":[137],"effects":[138],"not":[139],"observed":[140],"earlier,":[141],"which":[142],"DLT.":[147],"proposed":[149],"2":[151,173],"6":[157,200],"weekly.":[159],"Among":[160,180],"19":[161],"patients":[162,182,201],"active":[164],"disease,":[165],"7":[166,186],"(37%)":[167],"achieved":[168],"complete":[169,192],"(CHR);":[172],"(11%)":[174],"(complete).":[179],"8":[181],"treated":[183],"CHR,":[185],"(87%)":[187],"improved":[188,209],"(4":[193],"partial":[196],"(3":[197],"All":[199],"intolerant":[202],"IFN-alpha-2b;":[207],"4":[208],"their":[210],"response.":[212],"results":[214],"show":[215],"that":[216],"is":[219],"easier":[220],"deliver":[222],"(once":[223],"weekly),":[224],"tolerated,":[226],"perhaps":[228],"more":[229],"effective":[230],"than":[231],"IFN-alpha.":[232]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":2},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":3},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":2}],"updated_date":"2026-11-03T10:50:19.383937","created_date":"2016-06-24T00:00:00"}